Cancer Risk Awareness and Concern among Women with a Family History of Breast or Ovarian Cancer.
Andersen MR, Thorpe J, Buist DS, Beatty JD, Watabayashi K, Hanson N, Resta R, Chubak J, Urban N. Cancer risk awareness and concern among women with a family history of breast or ovarian cancer. Behav Med. 2014 Jul 25:0. [Epub ahead of print]
Identification of novel candidate plasma metabolite biomarkers for distinguishing serous ovarian carcinoma and benign serous ovarian tumors.
Buas MF, Gu H, Djukovic D, Zhu J, Drescher CW, Urban N, Raftery D, Li CI. Identification of novel candidate plasma metabolite biomarkers for distinguishing serous ovarian carcinoma and benign serous ovarian tumors. Gynecol Oncol. 2015 Oct 30. pii: S0090-8
Evaluating Serum Markers for Hormone Receptor-Negative Breast Cancer.
Schummer M, Thorpe J, Giraldez M, Bergan L, Tewari M, Urban N. Evaluating Serum Markers for Hormone Receptor-Negative Breast Cancer. PLoS One. 2015 Nov 13;10(11):e0142911. doi: 10.1371/journal.pone.0142911. eCollection 2015.
Identifying post-menopausal women at elevated risk for epithelial ovarian cancer.
Urban N, Hawley S, Janes H, Karlan BY, Berg CD, Drescher CW, Manson JE, Palomares MR, Daly MB, Wactawski-Wende J, O’Sullivan MJ, Thorpe J, Robinson RD, Lane D, Li CI, Anderson GL. Identifying post-menopausal women at elevated risk for epithelial ovarian c
Leveraging biospecimen resources for discovery or validation of markers for early cancer detection.
Schully SD, Carrick DM, Mechanic LE, Srivastava S, Anderson GL, Baron JA, Berg CD, Cullen J, Diamandis EP, Doria-Rose VP, Goddard KA, Hankinson SE, Kushi LH, Larson EB, McShane LM, Schilsky RL, Shak S, Skates SJ, Urban N, Kramer BS, Khoury MJ, Ransohoff D
Validation of LRG1 as a potential biomarker for detection of epithelial ovarian cancer by a blinded study.
Wu J, Yin H, Zhu J, Buckanovich RJ, Thorpe JD, Dai J, Urban N, Lubman DM. Validation of LRG1 as a potential biomarker for detection of epithelial ovarian cancer by a blinded study. PLoS One. 2015 Mar 23;10(3):e0121112. doi: 10.1371/journal.pone.0121112. e
Preclinical safety and efficacy studies with an affinity-enhanced epithelial junction opener and PEGylated liposomal doxorubicin.
Richter M, Yumul R, Wang H, Saydaminova K, Ho M, May D, Baldessari A, Gough M, Drescher C, Urban N, Roffler S, Zubieta C, Carter D, Fender P, Lieber A. Preclinical safety and efficacy studies with an affinity-enhanced epithelial junction opener and PEGyla
Use of CA125 and HE4 serum markers to predict ovarian cancer in elevated-risk women.
Karlan BY, Thorpe J, Watabayashi K, Drescher CW, Palomares M, Daly MB, Paley P, Hillard P, Andersen MR, Anderson G, Drapkin R, Urban N. Use of CA125 and HE4 Serum Markers to Predict Ovarian Cancer in Elevated-Risk Women. Cancer Epidemiol Biomarkers Prev.
Outcome of unexpected adnexal neoplasia discovered during risk reduction salpingo-oophorectomy in women with germ-line BRCA1 or BRCA2 mutations.
Conner JR, Meserve E, Pizer E, Garber J, Roh M, Urban N, Drescher C, Quade BJ, Muto M, Howitt BE, Pearlman MD, Berkowitz RS, Horowitz N, Crum CP, Feltmate C. Outcome of unexpected adnexal neoplasia discovered during risk reduction salpingo-oophorectomy in
Longitudinal screening algorithm that incorporates change over time in CA125 levels identifies ovarian cancer earlier than a single-threshold rule.
Drescher CW, Shah C, Thorpe J, O’Briant K, Anderson GL, Berg CD, Urban N, McIntosh MW. Longitudinal screening algorithm that incorporates change over time in CA125 levels identifies ovarian cancer earlier than a single-threshold rule. J Clin Oncol. 2013 J
More Publications
